Fluoropyrimidines: A Cardiotoxicity Case for Caution.

ABSTRACT:

Background

Fluoropyrimidines are widely used in cancer treatment but can cause cardiac adverse effects.

Case summary

A 57-year-old man with esophageal cancer, receiving fluoropyrimidine-based therapy, was referred for preoperative cardiac evaluation. Abnormal electrocardiogram findings raised concern for ischemia, but coronary angiography ruled out obstructive disease. Fluoropyrimidine-induced coronary vasospasm was suspected, and calcium channel blocker therapy was initiated. Five months later, after tumor recurrence, continuous fluoropyrimidine infusion was restarted without cardiology consultation, and calcium channel blocker therapy had been discontinued. The patient developed cardiogenic shock and died.

Why beyond the guidelines

Current guidelines provide limited

SUBMITTER: von Stein P 

PROVIDER: S-EPMC12402353 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature